Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Vivione Biosciences Inc. to Hold Product Demonstration on September 11 in Calgary

V.VBI.H

Vivione Biosciences Inc. (“Vivione”) (TSXV:VBI), a rapid bacteria detection company, is pleased to announce that following its annual and special shareholder meeting at 10 a.m. on September 11, there will be a demonstration of its new oil and gas diagnostic offering from 1 p.m. to 4 p.m. at the office of Borden Ladner Gervais LLP, located at Centennial Place, East Tower, 1900, 520 3rd Avenue S.W., Calgary, Alberta, Canada.

This new offering, which was formally announced last July, materialized through a strategic alliance between Vivione and the Institute for Environmental Health, Inc. Through this partnership, Vivione can now offer its customers a clinical approach to identifying and quantifying bacterial contamination levels in oil and gas environments. In addition to providing a demonstration of the new offering, Vivione will recount the exciting developments of the past year, as well as give shareholders a preview of the company’s strategy moving forward.

The company will also be introducing Justin Springfield as the new Senior Vice President of Sales & Marketing. Mr. Springfield comes to Vivione with 16 years of experience in the pharmaceutical industry, and will be using this expertise to ensure a cohesive team effort for the company’s designated focus areas for 2015. The former Senior Vice President of Sales & Marketing, Steve Roon, resigned in August and will be continuing on as a consultant with Vivione throughout the next year.

About Vivione

Formed in 2006 in collaboration with the FDA, Vivione is a TSX Venture Exchange listed biosciences company focused on the commercialization of its proprietary RAPID-B system; an integrated system of hardware, software and chemical reagents that quickly and accurately identify, quantify and qualify bacteria and other pathogens in food safety, bio-therapeutics, clinical, industrial and oil & gas environments. For more information, visit www.VivioneBiosciences.com.

Cautionary Statements

This news release contains "forward-looking statements" within the meaning of applicable securities laws. Although Vivione believes that the expectations reflected in its forward-looking statements are reasonable, such statements have been based on factors and assumptions concerning future events that may prove to be inaccurate. These factors and assumptions are based upon currently available information to Vivione. Such statements are subject to known and unknown risks, uncertainties and other factors that could influence actual results or events and cause actual results or events to differ materially from those stated, anticipated or implied in the forward-looking statements. This news release contains forward-looking information relating to the commercialization and the development of the RAPID-B system and the success of Vivione’s oil and gas offering and Vivione’s business and growth strategy and the commercialization. Readers are cautioned to not place undue reliance on forward-looking statements. The statements in this news release are made as of the date of this news release and, except as required by applicable law, Vivione does not undertake any obligation to publicly update or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise. Vivione undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of Vivione, or its financial or operating results or (as applicable) their securities.

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.